- the best-corrected visual acuity is between 6/12 and 6/96
- there is no permanent structural damage to the fovea
- the lesion size is no larger than 12 disc areas in greatest linear dimension
- there is evidence of recent presumed disease progression (blood vessel growth, as indicated by fluorescein angiography, or recent visual acuity changes)
The drug must be provided by the manufacturer with the discount as agreed in the patient access scheme.